Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Dec;115(12):1651-9.
doi: 10.1007/s00702-008-0136-2. Epub 2008 Oct 30.

Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial

Holger Kessler  1 , Frank-Gerald Pajonk, Daniela Bach, Thomas Schneider-Axmann, Peter Falkai, Wolfgang Herrmann, Gerd Multhaup, Jens Wiltfang, Stephanie Schäfer, Oliver Wirths, Thomas A Bayer
Affiliations
Clinical Trial

Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial

Holger Kessler et al. J Neural Transm (Vienna). 2008 Dec.

Abstract

A plethora of reports suggest that copper (Cu) homeostasis is disturbed in Alzheimer's disease (AD). In the present report we evaluated the efficacy of oral Cu supplementation on CSF biomarkers for AD. In a prospective, randomized, double-blind, placebo-controlled phase 2 clinical trial (12 months long) patients with mild AD received either Cu-(II)-orotate-dihydrate (verum group; 8 mg Cu daily) or placebo (placebo group). The primary outcome measures in CSF were Abeta42, Tau and Phospho-Tau. The clinical trial demonstrates that long-term oral intake of 8 mg Cu can be excluded as a risk factor for AD based on CSF biomarker analysis. Cu intake had no effect on the progression of Tau and Phospho-Tau levels in CSF. While Abeta42 levels declined by 30% in the placebo group (P = 0.001), they decreased only by 10% (P = 0.04) in the verum group. Since decreased CSF Abeta42 is a diagnostic marker for AD, this observation may indicate that Cu treatment had a positive effect on a relevant AD biomarker. Using mini-mental state examination (MMSE) and Alzheimer disease assessment scale-cognitive subscale (ADAS-cog) we have previously demonstrated that there are no Cu treatment effects on cognitive performance, however. Finally, CSF Abeta42 levels declined significantly in both groups within 12 months supporting the notion that CSF Abeta42 may be valid not only for diagnostic but also for prognostic purposes in AD.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Neural Transm (Vienna). 2008 Aug;115(8):1181-7 - PubMed
    1. Brain Pathol. 2001 Jan;11(1):1-11 - PubMed
    1. Am J Clin Nutr. 2004 Jun;79(6):1037-44 - PubMed
    1. J Biol Chem. 2004 Dec 10;279(50):51958-64 - PubMed
    1. Arch Neurol. 2004 May;61(5):738-43 - PubMed

Publication types

MeSH terms

LinkOut - more resources